Filing Flows › Tango Therapeutics (TNGX) › Q3 2025
Tango Therapeutics (TNGX) Q3 2025 earnings results (third quarter 2025)
10-Q filed Nov 4, 2025
Tango Therapeutics (TNGX) reported revenue of $53.8M for the third quarter 2025 (Q3 2025), +364% from a year earlier and up 17-fold from the quarter before. Operating margin was 26.2%, net earnings $15.9M (29.5% of revenue).
Tango Therapeutics, Q3 2025: revenue $53.8M (+364% year over year), operating margin 26.2%, net earnings $15.9M, operating cash flow −$31.0M. The chart follows the revenue to costs, profit and cash.
| Q3 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $53.8M | 17× | +364% |
| Operating profit | $14.1M | — | — |
| Net earnings | $15.9M | — | — |
| Operating cash flow | −$31.0M | — | — |
What changed
Revenue was $53.8M in Q3 2025, up 364% year over year and up 1592% from the previous quarter.
Operating profit was $14.1M, a 26.2% margin (up 309.4 points year over year). Total costs fell 11% while revenue rose 364%. Net earnings were $15.9M. The effective tax rate was -0.1%.
Operating cash flow was −$31.0M. Non-cash charges added back $555K of depreciation and $6.6M of share-based compensation. Working capital and other items used $54.0M. Capital expenditures of $151K exceeded it, leaving free cash flow of −$31.1M.
Questions
What was Tango Therapeutics' revenue in the third quarter 2025?
Tango Therapeutics (TNGX) reported revenue of $53.8M for the third quarter 2025 (Q3 2025), +364% from a year earlier and up 17-fold from the quarter before.
Was Tango Therapeutics profitable in the third quarter 2025?
Operating profit was $14.1M (26.2% of revenue) and net earnings $15.9M.
Source: Tango Therapeutics 10-Q on SEC EDGAR.